Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

• Váldodahkkit: Shan Jing (Dahkki), Yang Lin (Dahkki), Randy Dockens (Dahkki), David Marchisin (Dahkki), Bing He (Dahkki), Ihab G. Girgis (Dahkki), Anjaneya Chimalakonda (Dahkki), Bindu Murthy (Dahkki), Urvi Aras (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Adis, Springer Healthcare, 2023-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Introduction Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and safety in healthy Chinese subjects. Methods This p...